Journal article
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
- Abstract:
-
Background The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event. Methods ARRIVE is a randomised, double-blind, placebo-controlled, multicentre study done in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascul... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 366.4KB)
-
- Publisher copy:
- 10.1016/s0140-6736(18)31924-x
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Journal website
- Volume:
- 392
- Issue:
- 10152
- Pages:
- 1036-1046
- Publication date:
- 2018-08-26
- Acceptance date:
- 2018-08-10
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
- Pmid:
-
30158069
- Source identifiers:
-
915413
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:915413
- UUID:
-
uuid:4e5a6dcf-538c-41e1-88b9-1cca43fdb87a
- Local pid:
- pubs:915413
- Deposit date:
- 2019-01-11
Terms of use
- Copyright holder:
- Elsevier Ltd
- Copyright date:
- 2018
- Notes:
- Copyright © 2018 Elsevier Ltd. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/s0140-6736(18)31924-x
If you are the owner of this record, you can report an update to it here: Report update to this record